Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Equity Average (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Equity Average for 15 consecutive years, with $145.1 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 13.05% to $145.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.1 million through Dec 2025, down 13.05% year-over-year, with the annual reading at $148.7 million for FY2025, 18.78% down from the prior year.
  • Equity Average for Q4 2025 was $145.1 million at Anika Therapeutics, down from $147.2 million in the prior quarter.
  • The five-year high for Equity Average was $288.6 million in Q4 2021, with the low at $145.1 million in Q4 2025.
  • Average Equity Average over 5 years is $236.0 million, with a median of $273.4 million recorded in 2021.
  • The sharpest move saw Equity Average rose 4.34% in 2022, then crashed 30.84% in 2024.
  • Over 5 years, Equity Average stood at $288.6 million in 2021, then fell by 1.15% to $285.2 million in 2022, then dropped by 15.38% to $241.4 million in 2023, then plummeted by 30.84% to $166.9 million in 2024, then fell by 13.05% to $145.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $145.1 million, $147.2 million, and $148.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.